Skip to Content

New Additions to Rxmed for 2016

We update the Rxmed database on a regular cycle. The following new drug information has been added this year:

Showing additions for:

Mar 23, 2016 - Cinqair (reslizumab) is an interleukin 5 antagonist monoclonal antibody (IgG4 kappa) indicated for add-on maintenance treatment of patients with severe asthma.

Mar 23, 2016 - Taltz (ixekizumab) is a humanized interleukin-17A antagonist indicated for the treatment of adults with moderate-to-severe plaque psoriasis.

Mar 7, 2016 - Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide) is a fixed-dose combination of emtricitabine (FTC) and tenofovir alafenamide (TAF), both HIV nucleoside analog reverse transcriptase inhibitors (NRTIs), and rilpivirine (RPV), a non-nucleoside reverse transcriptase inhibitor (NNRTI), indicated as a complete regimen for the treatment of HIV-1 infection.

Feb 24, 2016 - Briviact (brivaracetam) is an analog of levetiracetam for the treatment of partial-onset seizures in patients with epilepsy.

Jan 29, 2016 - Zepatier (elbasvir and grazoprevir) is a once-daily, single tablet, NS5A replication complex inhibitor and NS3/4A protease inhibitor combination for the treatment of chronic hepatitis C virus (HCV) genotypes 1 and 4 infections.

Browse additions by year: